Test IMP without active substance
Sponsors
Alpine Immune Sciences Inc., Vertex Pharmaceuticals Inc.
Conditions
Generalized Myasthenia GravisImmunoglobulin A NephropathyPrimary Membranous Nephropathy
Phase 2
A Phase 2b/3 Adaptive, Randomized, Active controlled Study Evaluating the Efficacy, Safety, and Tolerability of Povetacicept Versus Calcineurin Inhibitor in the Treatment of Primary Membranous Nephropathy
RecruitingCTIS2025-521661-27-00
Start: 2025-12-19Target: 30Updated: 2025-12-16
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a Long-term Extension of Povetacicept in Adults with Generalized Myasthenia Gravis
Not yet recruitingCTIS2025-523950-15-01
Target: 5Updated: 2026-05-29